119 completed, 32 recruiting, 31 terminated, 17 unknown. 95 Phase 1, 89 Phase 2, 21 Phase 3, 16 Not applicable, 6 Early Phase 1.
Follow Leukemia, T-Cell: new trials by email Literature Review of Leukemia, T-Cell trials Research Report on Leukemia, T-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-09-30 | 2026-07-06 |
| A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia zeprumetostat - Large Granular Lymphocyte Leukemia, T-LGL Leukemia | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-08-30 | 2026-09-21 |
| Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia | Recruiting | Rong Tao | 1500 | 2026-08-11 | 2026-08-13 | |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) - HTLV-1 Infection, HTLV I Associated Myelopathies | Phase 2 | Recruiting | Carlos Brites | 146 | 2026-05-07 | 2026-06-02 |
| Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia Ruxolitinib, Cladribine, Venetoclax - T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-04-28 | 2026-08-12 |
| Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) Treatment Arm A - Leukemia, Myeloid, Acute, Leukemia, B-cell | Phase 1 | Recruiting | Baylor College of Medicine | 78 | 2026-04-15 | 2026-09-16 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Jonathan Brammer | 44 | 2026-02-12 | 2026-04-15 |
| Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). CART84 - Acute Myeloblastic Leukaemia, Leukemia, T-Cell | Phase 1 / Phase 2 | Recruiting | Gyala Therapeutics | 33 | 2026-02-04 | 2026-03-13 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib, Venetoclax - T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 12 | 2025-05-02 | 2026-07-17 |
| Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma Allogeneic anti-CD7 CAR-T cells (BEAM-201) - T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | Recruiting | Stephan Grupp MD PhD | 33 | 2025-04-29 | 2026-07-07 |
| Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies Anti-CD5 CAR NK cells - T-ALL/Lymphoma | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 15 | 2025-03-27 | 2025-04-03 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients TBICy, BuCy - T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 430 | 2024-12-01 | 2024-11-05 |
| A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 Mogamulizumab - T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 134 | 2024-11-15 | 2026-03-05 |
| PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas PI3K inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 51 | 2024-08-10 | 2025-08-12 |
| Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia Thalidomide and methotrexate - T-LGL Leukemia, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-08-10 | 2025-11-18 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
Showing 20 of 222. Sign in to see all of them.
Leukemia, Large Granular Lymphocytic (142) · Leukemia, Lymphocytic, Chronic, B-Cell (119) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (109) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (107) · Lymphoma, Non-Hodgkin (102) · Lymphoma, T-Cell, Cutaneous (101) · Lymphoma, Large-Cell, Anaplastic (95) · Lymphoma, Mantle-Cell (95) · Lymphoma, Follicular (94) · Lymphoma, Large B-Cell, Diffuse (94) · Immunoblastic Lymphadenopathy (93) · Mycosis Fungoides (93) · Sezary Syndrome (92) · Hodgkin Disease (91) · Leukemia, Hairy Cell (89)
Hemic and Lymphatic Diseases (222) · Immune System Diseases (222) · Immunoproliferative Disorders (222) · Lymphatic Diseases (222) · Neoplasms by Histologic Type (222) · Hematologic Diseases (221) · Leukemia, Lymphoid (218) · Neoplasms (203) · Lymphoproliferative Disorders (198) · Leukemia (143) · Pathologic Processes (133) · Pathological Conditions, Signs and Symptoms (133) · Disease Attributes (131) · Chronic Disease (122)
Cyclophosphamide (25) · fludarabine phosphate (23) · Peripheral Blood Stem Cell Transplantation (21) · Cyclosporine (17) · Mycophenolic Acid (16) · Whole-Body Irradiation (16) · Etoposide (13) · Methotrexate (10) · Cytarabine (9) · Alemtuzumab (8) · fludarabine (8) · Doxorubicin (7) · Melphalan (7) · Bortezomib (6) · Cyclosporins (6)
National Cancer Institute (NCI) (25) · Fred Hutchinson Cancer Center (16) · M.D. Anderson Cancer Center (10) · Institute of Hematology & Blood Diseases Hospital, China (7) · Case Comprehensive Cancer Center (6) · Jonsson Comprehensive Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · Northwestern University (5) · Barbara Ann Karmanos Cancer Institute (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · German CLL Study Group (4) · Alliance for Clinical Trials in Oncology (3) · Beijing Boren Hospital (3) · Children's Oncology Group (3) · City of Hope Medical Center (3)
United States (162) · China (25) · Germany (16) · Italy (14) · Japan (11) · France (10) · Belgium (6) · Canada (5) · Spain (5) · Switzerland (5) · Australia (3) · Denmark (3) · Netherlands (3) · Slovakia (3) · Turkey (Türkiye) (3)
Brenda Sandmaier (5) · David Maloney (4) · Jonathan Brammer, MD (4) · John A. Glaspy, MD, MPH (3) · Mohamed Sorror (3) · Tapan Kadia, MD (3) · Thomas A Waldmann, M.D. (3) · Abhinav Deol, M.D. (2) · Ann Woolfrey (2) · Elisabeth Paietta, PhD (2) · Hongyu Zhang, MD/PhD (2) · Jorge Cortes, MD (2) · Richard K. Burt, MD (2) · Ryotaro Nakamura (2) · Shuhua Yi, Doctor (2)
PMID 32499241, PMID 15459300, PMID 16710026, PMID 17020988, PMID 17119113, PMID 17397698, PMID 18327587, PMID 18698002, PMID 19170225, PMID 19199905, PMID 19841031, PMID 19900571, PMID 22259028, PMID 22312108, PMID 22480131, PMID 23212516, PMID 23321252, PMID 23358983, PMID 23512246, PMID 23524863, PMID 23810788, PMID 24327518, PMID 24474568, PMID 25733162, PMID 25795722, PMID 26175532, PMID 26213141, PMID 26659919, PMID 26700120, PMID 26700123, PMID 26765645, PMID 26853648, PMID 27020837, PMID 27424289, PMID 27621400, PMID 28053024, PMID 28054442, PMID 28672195, PMID 29292843, PMID 29383130, PMID 29846250, PMID 30205939, PMID 30234404, PMID 30405781, PMID 30562587, PMID 30975030, PMID 31101621, PMID 31248843, PMID 31401903, PMID 31533931
P30CA015704 (15), P01CA018029 (7), P30CA016672 (4), P30CA043703 (4), P30CA072720 (4), U01CA097452 (3), N01CM62202 (2), P30CA015083 (2), P30CA016086 (2), P30CA022453 (2), P30CA033572 (2), P30CA068485 (2), U01CA062502 (2), U01CA062505 (2), U10CA032102 (2)